Perioperative risk of pancreatic head resection—nomogram-based prediction of severe postoperative complications as a decisional aid for clinical practice

J. Hipp · L. Rist · S. Chikhladze · D. A. Ruess · S. Fichtner-Feigl · U. A. Wittel

Received: 10 May 2021 / Accepted: 29 December 2021 / Published online: 23 March 2022
© The Author(s) 2022

Abstract

Purpose To develop nomograms for pre- and early-postoperative risk assessment of patients undergoing pancreatic head resection.

Methods Clinical data from 956 patients were collected in a prospectively maintained database. A test (n = 772) and a validation cohort (n = 184) were randomly generated. Uni- and multi-variate analysis and nomogram construction were performed to predict severe postoperative complications (Clavien-Dindo Grades III–V) in the test cohort. External validation was performed with the validation cohort.

Results We identified ASA score, indication for surgery, body mass index (BMI), preoperative white blood cell (WBC) count, and preoperative alkaline phosphatase as preoperative factors associated with an increased perioperative risk for complications. Additionally to ASA score, BMI, indication for surgery, and the preoperative alkaline phosphatase, the following postoperative parameters were identified as risk factors in the early postoperative setting: the need for intraoperative blood transfusion, operation time, maximum WBC on postoperative day (POD) 1–3, and maximum serum amylase on POD 1–3. Two nomograms were developed on the basis of these risk factors and showed accurate risk estimation for severe postoperative complications (ROC-AUC-values for Grades III–V—preoperative nomogram: 0.673 (95%, CI: 0.626–0.721); postoperative nomogram: 0.734 (95%, CI: 0.691–0.778); each \( p \leq 0.001 \)). Validation yielded ROC-AUC-values for Grades III–V—preoperative nomogram of 0.676 (95%, CI: 0.586–0.766) and postoperative nomogram of 0.677 (95%, CI: 0.591–0.762); each \( p = 0.001 \).

Conclusion Easy-to-use nomograms for risk estimation in the pre- and early-postoperative setting were developed. Accurate risk estimation can support the decisional process, especially for IPMN-patients with an increased perioperative risk.

Keywords Nomogram · Perioperative risk · Pancreatic head resection · Pancreatic cancer · IPMN

Introduction

Despite ongoing progress in surgical technique and perioperative management of patients, pancreatic head resection remains a challenging procedure with a substantial rate of perioperative complications and perioperative mortality. While surgical resection of pancreatic ductal adenocarcinoma (PDAC) and other malignant tumors of the pancreas is inevitable and in most cases the patient’s only chance for cure, the decision for surgical resection due to benign and premalignant lesions has to be weighed between the risk of malignant transformation on the one hand and surgical risk and postoperative quality of life on the other hand [1]. Especially in patients with intraductal papillary mucinous neoplasms (IPMN) there is a risk of overtreatment for patients with no risk factors and worrisome features from an oncological perspective [2] and—simultaneously—these patients are at increased risk of postoperative complications after pancreatic head resection [3]. A well-considered recommendation has to be offered to a patient by the treating physicians in this situation.

A nomogram is a simple tool which creates a graphic representation of a statistical predictive model [4]. Risk scores
and nomograms can help surgeons assess the individual risk of a patient’s procedure and can help to guide the decision-making process with a patient to achieve informed consent as well [5].

While a variety of risk scores for prediction of oncologic survival after resection of PDAC exist [6–11], predictive risk scores or nomograms for summarized postoperative surgical outcome are lacking besides specialized models for the prediction of pancreatic fistula [12, 13], intraabdominal infectious complications after pancreatic resection [14], and the risk of postoperative mortality after pancreatic surgery [15, 16].

Therefore, the first aim of our study was the development of a simple-to-use nomogram to preoperatively estimate the perioperative risk of severe complications following pancreatic head resection to support the preoperative decisional process. The second aim of our study was the development of a postoperative nomogram to predict the probability of severe complications in the postoperative course on the basis of information available at the end of the third postoperative day.

Methods

Patient selection

Patient data from 956 consecutive pancreatic head resections for several indications were collected in a prospectively-maintained database and evaluated retrospectively. Operations were performed between August 2001 and October 2018. The study was reviewed and approved by the Ethics Committee of the University of Freiburg (EK 85/20).

Data management

According to the study protocol, the following clinical and laboratory data were extracted from the prospectively-maintained database: demographic data (age, gender), clinical data (indication for surgery, ASA score [17], body mass index (BMI), performed operation including reconstruction, intraoperative blood loss, intraoperative blood transfusions, operation time, texture of pancreatic tissue, postoperative complications, diagnostics of complications, and treatment of complications and all available laboratory data of routine laboratory monitoring. Complications were classified according to the Clavien-Dindo general classification of complications [18] and the comprehensive complication index (CCI) [19]. Pancreatic surgery-specific complications such as postoperative pancreatic fistula (POPF) [20], delayed gastric emptying (DGE) [21], and post-pancreatectomy hemorrhage (PPH) [22] were classified according to International Study Group of Pancreatic Surgery (ISGPS) definitions.

All available results of the routine perioperative laboratory monitoring were collected from the preoperative laboratory evaluation to postoperative day (POD) 14. Laboratory samples were categorized according to the postoperative time, beginning from the preoperative sample (POD 1) to the postoperative samples on POD 1 to 3 (POD 1–3), POD 4 to 6 (POD 4–6), POD 7 to 9 (POD 7–9), and POD 10 to 14 (POD 10–14). For each time interval, the maximum observed value of a certain parameter was chosen as the value for the corresponding time interval. The following parameters of routine laboratory monitoring from blood-samples were collected in the study database: white blood cell (WBC) count, C-reactive protein (CRP), procalcitonin (PCT), serum amylase (amylase), serum lipase (lipase), aspartate aminotransferase/glutamate oxaloacetate transaminase (AST/GOT), alanine aminotransferase/glutamate pyruvate transaminase (ALT/GPT), gamma-glutamyltransferase (GGT), alkaline phosphatase (AP), serum total bilirubin (bilirubin), creatinine and blood urea nitrogen (BUN), the preoperative carbohydrate antigen 19-9 (CA19-9) value, the preoperative International Normalized Ratio (INR) value, and the preoperative partial thromboplastin time (PTT). Drainage samples were evaluated for drain amylase on the first three postoperative days. Acute kidney injury on POD 1–3 was diagnosed when creatinine increased 1.5 times over the preoperative value according to RIFLE-criteria [23].

Statistical analysis

Patients were randomly assigned to two groups of about 80% and 20% of the entire cohort. A total of 772 patients (80.8%) were assigned to the test cohort and 184 (19.2%) were assigned to the validation cohort. Results are expressed as median ± interquartile range (IQR) or as number (percentage). Categorical variables were compared using Pearson’s chi-square test. Mann-Whitney U-test or Kruskal-Wallis test with Mann-Whitney U-post hoc test and Bonferroni correction were used for descriptive analysis of non-parametric variables.

As the aim of this study was the development of a diagnostic screening tool to select patients at risk for postoperative complications after pancreatic head resection, patients of the test cohort were grouped according to Clavien-Dindo classification Grades 0–II and III–V. Univariate analysis was performed using Pearson’s chi-square test or Mann-Whitney U-test as applicable. Variables with a p-value < 0.1 were included in multivariate analysis. In addition to this variable selection, only one variable of possibly confounding variables (e.g., only one variable for each organ system) was selected for multivariate analysis and—in respect of the study aim—only preoperatively-known parameters.
were included in the multivariate analysis for the preoperative nomogram and only parameters with a known outcome on POD 3 were included in the variable selection for the multivariate analysis of the postoperative nomogram. For multivariate analysis and nomogram development, continuous variables were dichotomized by the optimal cutoff-value according to the results of the receiver operating characteristics (ROC) analysis with Youden index calculation [24]. Cutoff-values below laboratory threshold values were set to the laboratory threshold value (GPT POD 1 and AP POD 1). Multivariate analysis was then performed by binary logistic regression with backward stepwise variable selection. Nomograms were constructed based on the developed multivariate models [25]. Internal validation in the test cohort was performed by bootstrap resampling with 100 repetitions. External validation was performed with the validation cohort and the area under the curve (AUC) of the ROC analysis. The fistula risk score (FRS) was calculated as previously reported by Callery et al. [26]. Statistical analysis was performed using SPSS version 24.0.0.1 (IBM Corp., Armonk, NY, USA) and R version 4.0.0 (R Foundation for Statistical Computing, Vienna, Austria) with RStudio (RStudio Inc., Boston, MA, USA) and additional packages rms, ggplot, and pROC. Differences were considered statistically significant at p < 0.05.

Results

Clinical and routine laboratory characteristics of test cohort

The clinical and laboratory characteristics of the test cohort are summarized in Tables 1 and 2 and of the validation cohort in “Supplementary information” Table S1. During the perioperative course, several parameters of routine laboratory monitoring of the patients showed statistically significant differences between patients with and without severe postoperative complications. WBC showed an early postoperative peak on POD 1–3— as expected—with decreasing values in both groups of patients on POD 4–6 followed by a second increase in both groups on POD 7–9. While the patients without severe complications also showed an increase in WBC on POD 7–9, patients with severe complications showed persistent leukocytosis on POD 10–14 and significantly elevated WBC during the entire postoperative course (Fig. 1A). CRP showed higher elevation on POD 1–3 in patients with severe complications and persisting CRP-values > 100 mg/l after POD 10 in contrast to adequately decreasing CRP-values in patients without severe complications (Fig. 1B). PCT showed elevated values in patients with severe complications as well, but was excluded from further statistical evaluation due to the low number of performed tests and a high degree of patient selection. Serum amylase showed a peak on POD 1–3 in patients with severe complications, indicating postoperative pancreatitis as a sign for developing POPF while serum amylase-values below clinical threshold value on POD 1–3 were associated with an uneventful postoperative course. Interestingly, although serum amylase normalized below clinical cutoff-value in both groups, high-normal amylase values (≥ 7 U/l) were seen in the group with postoperative complications while significantly lower-normal values were observed in those patients without complications (Fig. 1C). Serum lipase values showed similar variations as the serum-amylase during the postoperative period. A significant difference between the patients with and without severe postoperative complications could be observed for the renal retention parameters creatinine and BUN for the entire perioperative time, indicating that chronic and acute renal failure are associated with perioperative risk of complications. The GOT showed an early peak on POD 1–3 in patients with complications, indicating its usefulness in diagnostics of postoperative liver perfusion complications. Bilirubin showed no differences in the early postoperative course but patients with complications showed elevated bilirubin after POD 7. An interesting observation was made concerning alkaline phosphatase. In our study cohort, higher preoperative values are associated with lower risk for postoperative complications. A statistically significant association between the texture of the pancreatic tissue and the preoperative value of alkaline phosphatase could be detected (p < 0.001). Correspondingly, a significant difference between the POPF and no POPF groups was observed as well (p < 0.001, Kruskal-Wallis ANOVA with Mann-Whitney U-post hoc test, Supplementary information Table S2).

Preoperative parameters associated with increased risk for perioperative complications

Univariate analysis revealed several parameters associated with perioperative complications Clavien-Dindo Grade III or higher (Tables 1 and 2). In the preoperative setting, the patient’s age, the indication for surgery, CA19-9 value, ASA score, BMI, WBC POD 1, GPT POD 1, AP POD 1, creatinine POD 1, and BUN POD 1 were significantly associated with postoperative complications. The indications for surgery were associated with different risks for postoperative complications. Pancreatic surgery for IPMN, bile duct cancer, duodenal cancer, and “Other indication” (including MCNs, SCNs, schwannoma, GIST, and sarcoma) was associated with a higher risk for complications, while surgical resection of PDAC, chronic pancreatitis, pancreatic neuroendocrine tumors (pNET), and pancreatic metastases was associated with a reduced perioperative risk. Therefore, the indications were classified as indications with a high risk
| Clinical data of test cohort | Clavien-Dindo Grades 0–II ($n = 565$) | Clavien-Dindo ≥ Grade III ($n = 207$) | $p$-value |
|-------------------------------|--------------------------------------|---------------------------------------|-----------|
| Age (years) ($n = 772$)       | 66 (55–74)                           | 67 (59–74)                           | 0.045#    |
| Gender                       |                                       |                                       | 0.612*    |
| Male                         | 316 (55.9%)                          | 120 (58.0%)                          |           |
| Female                       | 249 (44.1%)                          | 87 (42.0%)                           |           |
| Disease                      |                                       |                                       | 0.001*    |
| PDAC                         | 324 (57.3%)                          | 97 (47.1%)                           |           |
| Distal bile duct cancer      | 35 (6.2%)                            | 25 (12.1%)                           |           |
| Duodenal carcinoma           | 12 (2.1%)                            | 12 (5.8%)                            |           |
| Metastases                   | 6 (1.1%)                             | 1 (0.5%)                             |           |
| pNET                         | 28 (5.0%)                            | 7 (3.4%)                             |           |
| IPMN                         | 37 (6.5%)                            | 23 (11.2%)                           |           |
| Chronic pancreatitis         | 86 (15.2%)                           | 23 (11.2%)                           |           |
| Other                        | 37 (6.5%)                            | 18 (8.7%)                            |           |
| Indication (risk-stratified) |                                       |                                       | < 0.001*  |
| Low-risk indication          | 444 (78.6%)                          | 128 (62.1%)                          |           |
| (PDAC, CP, pNET, metastases) | 121 (24.4%)                          | 78 (37.9%)                           |           |
| High-risk indication         |                                       |                                       | 0.001*    |
| (IPMN, bile duct cancer, duodenal cancer, other indications) | | | |
| ASA score                    |                                       |                                       | 0.001*    |
| ASA 1–2                      | 313 (62.2%)                          | 93 (48.4%)                           |           |
| ASA 3–4                      | 190 (37.8%)                          | 99 (51.6%)                           |           |
| BMI                          |                                       |                                       | 0.023*    |
| BMI < 30 Kg/m²               | 515 (91.2%)                          | 177 (85.5%)                          |           |
| BMI ≥ 30Kg/m²                | 50 (8.8%)                            | 30 (14.5%)                           |           |
| Preoperative CA19-9 (U/ml) ($n = 487$) | 42.6 (14.5–256.15) | 28.5 (10–116) | 0.032# |
| Stent/PTCD preoperative      |                                       |                                       | 0.211*    |
| No                           | 291 (52.2%)                          | 117 (57.4%)                          |           |
| Yes                          | 266 (47.8%)                          | 87 (42.6%)                           |           |
| Operation                    |                                       |                                       | 0.573*    |
| Whipple procedure            | 59 (10.4%)                           | 26 (12.6%)                           |           |
| PPPD                         | 382 (67.6%)                          | 141 (68.1%)                          |           |
| Lap. ass. PPPD               | 124 (21.9%)                          | 40 (19.3%)                           |           |
| Portal vein resection        |                                       |                                       | 0.150*    |
| No                           | 429 (76.1%)                          | 166 (81.0%)                          |           |
| Yes                          | 135 (23.9%)                          | 39 (19.0%)                           |           |
| Multivisceral resection      |                                       |                                       | 0.971*    |
| No                           | 507 (89.9%)                          | 185 (89.8%)                          |           |
| Yes                          | 57 (10.1%)                           | 21 (10.2%)                           |           |
| Neoadjuvant treatment (PDAC patients) | 299 (95.2%) | 91 (95.8%) | 0.818* |
| No                           | 299 (95.2%)                          | 91 (95.8%)                           |           |
| Yes                          | 15 (4.8%)                            | 4 (4.2%)                             |           |
| Adjuvant treatment (PDAC patients) | 43 (16.0%) | 26 (32.5%) | 0.001* |
| No                           | 43 (16.0%)                           | 26 (32.5%)                           |           |
| Yes                          | 225 (84.0%)                          | 54 (67.5%)                           |           |
| Operation time (min.) ($n = 771$) | 418 (352–475) | 440 (376–522) | < 0.001# |
| Intraoperative blood loss (ml) ($n = 453$) | 600 (400–950) | 600 (400–1 175) | 0.409# |
| Intraoperative blood transfusion | 492 (87.1%) | 153 (73.9%) | < 0.001* |
| No                           | 492 (87.1%)                          | 153 (73.9%)                          |           |
| Yes                          | 73 (12.9%)                           | 54 (26.1%)                           |           |
(IPMN, bile duct cancer, duodenal cancer, and “Other indications”) and indications with a low risk (PDAC, CP, pNET, and metastases) for postoperative complications. Multivariate analysis identified indication (risk-stratified), ASA score, BMI, WBC POD 1, and preoperative alkaline phosphatase as independent risk factors for postoperative complications (Table 3).

### Perioperative parameters associated with increased risk for perioperative complications

The associations of perioperative parameters with a clinically known outcome on the third postoperative day and postoperative complications were evaluated. Added to the preoperatively known parameters, operation time, the need for intraoperative blood transfusion, texture of pancreatic tissue, maximum drain amylase on POD 1–3, WBC POD 1–3, CRP POD 1–3, PCT POD 1–3, (serum) amylase POD 1–3, (serum) lipase POD 1–3, GOT POD 1–3, GPT POD 1–3, creatinine POD 1–3, BUN POD 1–3, and acute kidney injury on POD 1–3 are associated with postoperative complications. Multivariate analysis revealed that the indication (risk-stratified), ASA score, BMI, the need for intraoperative blood transfusion, prolonged operation time, WBC POD 1–3, (serum) amylase POD 1–3, and the preoperative alkaline phosphatase were independent prognostic factors of postoperative complications Clavien-Dindo Grade III or higher (Table 4). The texture of the pancreatic tissue is correlated with AP POD 1 and serum amylase POD 1–3, and therefore, these quantifiable variables without interobserver variability were used for multivariate analysis.

### Nomograms for prediction of postoperative complications

Based on the results of the multivariate analyses, two nomograms were developed (Fig. 2A and B, a step-by-step user instruction is available in the “Supplementary information”
## Table 2  Perioperative course of routine laboratory parameters of test cohort

| Parameter | Clavien-Dindo Grades 0–II ($n = 565$) | Clavien-Dindo ≥ Grade III ($n = 207$) | $p$-value |
|-----------|--------------------------------------|--------------------------------------|-----------|
| WBC POD 1 ($x10^3/μl$) ($n = 751$) | 7.06 (5.76–8.60) | 7.20 (6.05–9.11) | 0.077# |
| WBC POD 1–3 ($x10^3/μl$) ($n = 764$) | 13.21 (10.80–15.97) | 14.40 (11.46–17.24) | 0.004# |
| WBC POD 4–6 ($x10^3/μl$) ($n = 746$) | 9.20 (7.24–11.58) | 11.50 (9.19–14.70) | < 0.001# |
| WBC POD 7–9 ($x10^3/μl$) ($n = 691$) | 10.17 (8.22–12.83) | 15.60 (11.96–21.43) | < 0.001# |
| WBC POD 10–14 ($x10^3/μl$) ($n = 650$) | 10.70 (8.10–13.71) | 17.07 (12.89–23.19) | < 0.001# |
| CRP POD 1 (mg/l) ($n = 298$) | 8 (5–19) | 12 (5–25) | 0.225# |
| CRP POD 1–3 (mg/l) ($n = 153$) | 127 (85–190) | 176 (133–271) | < 0.001# |
| CRP POD 4–6 (mg/l) ($n = 413$) | 81 (46–127) | 151 (91–286) | < 0.001# |
| CRP POD 7–9 (mg/l) ($n = 522$) | 53 (27–93) | 128 (88–235) | < 0.001# |
| CRP POD 10–14 (mg/l) ($n = 503$) | 38 (18–84) | 119 (59–221) | < 0.001# |
| PCT POD 1 (ng/ml) ($n = 33$) | 0.13 (0.08–0.25) | 0.16 (0.09–1.38) | 0.375# |
| PCT POD 1–3 (ng/ml) ($n = 52$) | 0.46 (0.27–0.91) | 1.18 (0.86–4.51) | < 0.001# |
| PCT POD 4–6 (ng/ml) ($n = 43$) | 0.17 (0.13–0.34) | 1.74 (0.42–4.39) | < 0.001# |
| PCT POD 7–9 (ng/ml) ($n = 38$) | 0.10 (0.08–0.28) | 1.52 (0.70–2.27) | < 0.001# |
| PCT POD 10–14 (ng/ml) ($n = 36$) | 0.17 (0.10–1.19) | 1.59 (0.89–5.05) | 0.008# |
| Amylase POD 1 (U/l) ($n = 676$) | 27 (15–49) | 27 (19–52) | 0.274# |
| Amylase POD 1–3 (U/l) ($n = 746$) | 47 (13–190) | 129 (42–379) | < 0.001# |
| Amylase POD 4–6 (U/l) ($n = 612$) | 8 (4–20) | 17 (9–39) | < 0.001# |
| Amylase POD 7–9 (U/l) ($n = 299$) | 6 (3–16) | 13 (7–22) | < 0.001# |
| Amylase POD 10–14 (U/l) ($n = 380$) | 8 (4–19) | 13 (7–27) | < 0.001# |
| Lipase POD 1 (U/l) ($n = 474$) | 48 (28–114) | 47 (28–104) | 0.818# |
| Lipase POD 1–3 (U/l) ($n = 198$) | 31 (10–194) | 103 (40–277) | 0.005# |
| Lipase POD 4–6 (U/l) ($n = 247$) | 10 (6–20) | 15 (9–32) | 0.004# |
| Lipase POD 7–9 (U/l) ($n = 267$) | 10 (7–21) | 18 (10–30) | 0.001# |
| Lipase POD 10–14 (U/l) ($n = 253$) | 14 (8–27) | 20 (11–41) | 0.004# |
| GOT POD 1 (U/l) ($n = 690$) | 33 (24–65) | 30 (24–56) | 0.247# |
| GOT POD 1–3 (U/l) ($n = 408$) | 77 (49–123) | 103 (59–183) | < 0.001# |
| GOT POD 4–6 (U/l) ($n = 418$) | 38 (26–54) | 40 (25–80) | 0.133# |
| GOT POD 7–9 (U/l) ($n = 398$) | 34 (24–51) | 36 (26–61) | 0.155# |
| GOT POD 10–14 (U/l) ($n = 388$) | 34 (24–46) | 36 (24–64) | 0.112# |
| GPT POD 1 (U/l) ($n = 506$) | 42 (22–108) | 32 (21–84) | 0.070# |
| GPT POD 1–3 (U/l) ($n = 377$) | 70 (41–136) | 78 (48–155) | 0.096# |
| GPT POD 4–6 (U/l) ($n = 392$) | 47 (29–77) | 51 (27–100) | 0.330# |
| GPT POD 7–9 (U/l) ($n = 370$) | 44 (29–71) | 46 (22–107) | 0.911 |
| GPT POD 10–14 (U/l) ($n = 359$) | 39 (25–66) | 36 (21–71) | 0.647# |
| GGT POD 1 (U/l) ($n = 526$) | 143 (38–439) | 102 (33–341) | 0.328# |
| GGT POD 1–3 (U/l) ($n = 380$) | 76 (32–209) | 84 (33–206) | 0.616# |
| GGT POD 4–6 (U/l) ($n = 405$) | 104 (51–213) | 91 (49–202) | 0.659# |
| GGT POD 7–9 (U/l) ($n = 394$) | 127 (77–269) | 167 (77–300) | 0.365# |
| GGT POD 10–14 (U/l) ($n = 384$) | 148 (78–277) | 197 (108–382) | 0.011# |
| AP POD 1 (U/l) ($n = 698$) | 133 (85–301) | 105 (74–234) | 0.002# |
| AP POD 1–3 (U/l) ($n = 325$) | 89 (60–178) | 86 (51–164) | 0.394# |
| AP POD 4–6 (U/l) ($n = 374$) | 114 (74–200) | 107 (75–167) | 0.412# |
| AP POD 7–9 (U/l) ($n = 375$) | 133 (89–210) | 126 (86–174) | 0.329# |
| AP POD 10–14 (U/l) ($n = 368$) | 140 (97–231) | 157 (107–255) | 0.145# |
| Bilirubin POD 1 (mg/dl) ($n = 708$) | 0.7 (0.4–2.2) | 0.7 (0.4–2.0) | 0.823# |
| Bilirubin POD 1–3 (mg/dl) ($n = 751$) | 0.9 (0.6–1.8) | 1.0 (0.6–2.0) | 0.314# |
| Bilirubin POD 4–6 (mg/dl) ($n = 658$) | 0.6 (0.3–1.2) | 0.7 (0.4–1.8) | 0.013# |
| Bilirubin POD 7–9 (mg/dl) ($n = 503$) | 0.4 (0.3–0.9) | 0.6 (0.4–1.2) | 0.003# |
Although not designed for this specific task, prediction of Clavien-Dindo Grades IV and V also was possible with the nomograms (Supplementary information Table S1 and Supplementary information Fig. S3). We compared our nomogram with the FRS—which is calculated postoperatively—in a cohort of 57 patients from our validation cohort, for which all data needed for the calculation of the FRS were available. AUC for prediction of complications Clavien-Dindo Grade III or higher was 0.672 (p = 0.030) for the FRS, 0.665 (p = 0.033) for the preoperative nomogram, and 0.674 (p = 0.020) for the postoperative nomogram. Therefore, both postoperative scores were almost equally efficient in the prediction of postoperative complications and the preoperative nomogram only slightly less accurate. Combination of the FRS and our nomograms by simple addition of normalized score values showed that the FRS and the preoperative nomogram improved the predictive accuracy to AUC 0.696 (p = 0.012) and the FRS and the postoperative nomogram to AUC 0.682 (p = 0.017).

### Different patterns of postoperative complications due to preoperative risk factors

When comparing the risk for certain postoperative complications, different patterns of complications due to the different preoperative risk factors can be observed. While patients with high-risk indications or a low preoperative alkaline phosphatase have a higher risk for POPF and subsequently a higher risk for postoperative sepsis, intensive care-associated complications such as pneumonia, thromboembolism, and acute renal failure are more likely to occur in patients with a higher ASA score. The first diagnostic procedure to diagnose postoperative complications was performed on POD 8 (4–11.5) (computed tomography: n = 212 and endoscopy: n = 54) and the first intervention surgery...
The first postoperative interventions are summarized in Table S6. Elevated WBC (≥ 12.5 × 10^3/μl) and CRP (≥ 85 mg/l) levels in the later postoperative course POD 7–9 implicate a higher rate of operative revision procedures and less interventional procedures, indicating a higher severity of the clinical condition of patients with these laboratory findings (Supplementary information Tables S5, S6, and S7).

**Table 3** Multivariate analysis of preoperative risk factors for postoperative complications ≥ Clavien-Dindo Grade III

| Variable                        | Odds ratio | 95%, CI       | p-value |
|---------------------------------|------------|---------------|---------|
| Indication (risk-stratified)    | Low-risk indication | Reference   | Reference | < 0.001 |
|                                 | High-risk indication | 2.106       | 1.421–3.121 |         |
| ASA score                       | ASA 1–2    | Reference     | Reference | 0.005   |
|                                 | ASA 3–4    | 1.690         | 1.176–2.431 |         |
| BMI                             | BMI < 30 Kg/m² | Reference   | Reference | 0.023   |
|                                 | BMI ≥ 30 Kg/m² | 1.879       | 1.089–3.242 |         |
| WBC POD 1                       | < 9.5 × 10^3 | Reference   | Reference | 0.015   |
|                                 | ≥ 9.5 × 10^3 | 1.762       | 1.115–2.786 |         |
| Alkaline phosphatase POD 1      | < 105 U/l  | Reference     | Reference | 0.016   |
|                                 | ≥ 105 U/l  | 0.634         | 0.437–0.920 |         |
Table 4 Multivariate analysis of perioperative (preoperative to POD 3) risk factors for postoperative complications ≥ Clavien-Dindo Grade III

| Variable                               | Odds ratio | 95%, CI     | p-value |
|----------------------------------------|------------|-------------|---------|
| Indication (risk-stratified)           |            |             |         |
| Low-risk indication                    | Reference  | Reference   | 0.005   |
| High-risk indication                   |            |             |         |
| ASA score                              |            |             |         |
| ASA 1–2                                | Reference  | Reference   | 0.003   |
| ASA 3–4                                | 1.807      | 1.225–2.667 |         |
| BMI                                    |            |             |         |
| BMI < 30 Kg/m²                         | Reference  | Reference   | 0.043   |
| BMI ≥ 30 Kg/m²                         | 1.813      | 0.019–3.224 |         |
| Intraoperative blood transfusion       |            |             |         |
| No                                    | Reference  | Reference   | 0.001   |
| Yes                                   | 2.376      | 1.407–4.012 |         |
| Operation time                         |            |             |         |
| < 450 min                              | Reference  | Reference   | 0.006   |
| ≥ 450 min                              | 1.746      | 1.173–2.600 |         |
| WBC POD 1–3                            |            |             |         |
| < 13.5 × 10³                           | Reference  | Reference   | 0.015   |
| ≥ 13.5 × 10³                           | 1.614      | 1.096–2.378 |         |
| Serum amylase POD 1–3                  |            |             |         |
| < 54 U/l                               | Reference  | Reference   | < 0.001 |
| ≥ 54 U/l                               | 2.641      | 1.731–4.028 |         |
| Alkaline phosphatase POD 1             |            |             |         |
| < 105 U/l                              | Reference  | Reference   | 0.063   |
| ≥ 105 U/l                              | 0.679      | 0.451–1.021 |         |

Fig. 2 Nomograms for the estimation of the perioperative risk of severe (Clavien-Dindo Grades III–V) complications after pancreatic head resection. A Preoperative nomogram. B Postoperative nomogram (POD 3). (Low-risk indication: PDAC, CP, pNET, and metastases; High-risk indication: IPMN, bile duct cancer, duodenal cancer, other indications)
Discussion

In this study, we were able to develop two nomograms for prediction of perioperative morbidity and mortality in the preoperative and perioperative setting. The nomograms demonstrated both high reliability in internal validation by bootstrap resampling as well as a good fitness in external validation with the completely independent validation cohort of this study.

The identified risk factors for the preoperative nomogram are the indication for surgery, the ASA score, the BMI, the preoperative WBC, and the preoperative alkaline phosphatase. The correlation between perioperative risks and the different indications for pancreatic head resection is well known. While surgical resection of PDAC and chronic pancreatitis is known to have less perioperative risk mainly due to fibrous pancreatic tissue and a lower risk of POPF, patients with IPMN, MCN, distal bile duct cancer, and duodenal cancer are at increased risk for POPF and postoperative complications [3, 26–28]. In our cohort, pNETs were surprisingly not associated with an increased risk of perioperative complications and therefore had to be stratified as a “low-risk indication”. Other authors describe an increased risk in pancreatic surgery for pNET compared to other indications [29, 30]. The ASA score is a well-established parameter for general evaluation of perioperative risk in surgery and for pancreatic surgery in particular as well [31, 32] and an increased body mass index is also a well-established risk factor for postoperative surgical and medical complications [29, 33, 34]. Preoperative WBC and especially postoperative WBC are known factors for the prediction of postoperative complications in general surgery [35, 36] and for pancreatic resections in particular [37, 38].

A very interesting observation was made in our data when analyzing the preoperative alkaline phosphatase levels. Patients with increased preoperative alkaline phosphatase levels ≥ 105 U/l were at decreased risk for postoperative complications and had less POPF. This association has not been described before and warrants further research. Alkaline phosphatase is known to be elevated in patients with malignant tumors of the pancreas [39], with IPMNs with progression during observation [40], and correlates with CA19-9 values [41]. A possible explanation of this observation is the known impact of pancreatic duct occlusion on alkaline phosphatase levels and a possible activation of fibroblasts in the pancreas due to this mechanism [42].

The postoperative nomogram consists of the preoperatively known parameters listed above without the preoperative WBC, and is enhanced with parameters with a known outcome on POD 3. The first new variable in the postoperative nomogram is a prolonged operation time. Earlier studies showed that operation time is an independent risk factor for an unfavorable postoperative outcome and should be considered as a relevant parameter in risk-adjustment processes and as a possible area of quality improvement on the individual and system level [43, 44]. Perioperative blood transfusions are known to be associated with an increased risk for postoperative complications [44, 45] and prudent patient-blood management with adequate transfusion triggers is essential for prevention of unnecessary transfusions.
advanced age [52], pre-existing elevated creatinine [53], and hyperlipasemia accurately predict the risk for POPF [47, 48]. Although postoperative serum amylase and postoperative serum lipase is used as a specific risk factor in prediction of pancreatic fistula in any relevant fistula risk score [49], alkaline phosphatase nor postoperative serum amylase or existing scoring systems. Interestingly, neither preoperative complications following pancreatic head resection, an odds ratio of 2.64 of patients with elevated serum amylase levels and the highest impact on the overall score of the postoperative nomogram can be observed in our cohort. Our nomograms for prediction of postoperative complications therefore have some similarities, but also differences to scores predicting POPF such as the ASA score, BMI, intraoperative blood transfusions, and the indication for pancreatic surgery are part of the fistula risk score (FRS) [26] or a recently-published nomogram [12]. Other scoring systems to predict POPF exist. A systematic review summarized the existing scoring systems. Interestingly, neither preoperative alkaline phosphatase nor postoperative serum amylase or serum lipase is used as a specific risk factor in prediction of pancreatic fistula in any relevant fistula risk score [49], although postoperative serum amylase and postoperative hyperlipasemia accurately predict the risk for POPF [47, 48].

Maximum drain-amylase levels on POD 1–3 [50, 51], advanced age [52], pre-existing elevated creatinine [53], and postoperative acute renal failure [54] are known risk factors for postoperative complications, but failed to improve the predictive value of the logistic regression models in our cohort and were therefore excluded during multivariate analysis.

Limitations of this study are, of course, the retrospective design of the study with the resultant missing laboratory data during the postoperative course and missing preoperative variables. Low protein and albumin levels for example are known predictors of postoperative complications after general [55] and pancreatic surgery [56]. These parameters were not routinely measured in our perioperative work-up of patients and therefore were not included in the nomogram development. During a prospective validation study of the nomograms, these parameters should additionally be obtained routinely for possible refinement of the predictive value of the risk scores. Additionally, radiological factors and probably the assessment of the pancreatic gland texture with the help of radiomics can further refine the risk assessment in the future.

Nevertheless, the established nomograms demonstrated good internal and external validity and improve the pre- and perioperative assessment of patients scheduled for pancreatic head resection. In our opinion, there are two main clinical applications for the preoperative nomogram. First of all, surgeons can assess the individual perioperative risk for a patient. For example, when combining our nomogram with risk scores for the prediction of malignancy in cystic tumors of the pancreas [57, 58], informed consideration of surgical risk and risk of malignancy can help to decide whether a surgical resection should be performed in patients at a higher risk for surgical complications. Secondly, the nomogram can aid in the decision-making process with a patient. With the help of this nomogram, a patient can better understand his individual risk and a decision for or against surgery can be made with better informed consent. The positive effect of a preoperative weight loss can also be demonstrated to obese patients in whom the resection is not urgently required, for example, in patients with prophylactic resection of IPMN with worrisome features. The postoperative nomogram can help to evaluate the individual risk of complications after the operation and might help to increase the awareness of the treatment team towards a high-risk patient and support early detection and early treatment of complications, thereby preventing the sequelae of delayed complication management.

In conclusion, we developed and validated two nomograms for prediction of severe perioperative complications in the preoperative and perioperative setting after pancreatic head resection. We could demonstrate that both nomograms also predict higher grade complications Clavien-Dindo Grades IV–V and V, respectively, making both nomograms a solid new tool for estimation of perioperative risk for an individual patient.

**Supplementary Information** The online version contains supplementary material available at [https://doi.org/10.1007/s00423-021-02426-z](https://doi.org/10.1007/s00423-021-02426-z).

**Acknowledgements** We thank Olivia Sick for administrative support and data management.

**Availability of data, codes, and material** The datasets and codes generated and analyzed during the current study are available from the corresponding author on reasonable request.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Declarations**

**Ethics approval** The study was reviewed and approved by the Ethics Committee of the University of Freiburg (EK 85/20).

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Weinberg BM, Spiegel BMR, Tomlinson JS, Farrell JJ (2010) Asymptomatic pancreatic cystic neoplasms: maximizing survival and quality of life using Markov-based clinical nomograms. Gastroenterology 138:531–540
2. Crippa S, Bassi C, Salvia R et al (2017) Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a midterm follow-up analysis. Gut 66:495–506
3. Hupp J, Mohamed S, Pott J et al (2019) Management and outcomes of intraductal papillary mucinous neoplasms. BJS open 3:490–499
4. Iasonos A, Schrag D, Raj GV, Panageas KS (2008) How to build and interpret a nomogram for cancer prognosis. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26:1364–1370
5. Kattan MW, Marasco J (2010) What is a real nomogram? Seminars in oncology 37:23–26
6. Dreyer SB, Pinese M, Jamieson NB, et al. (2018) Precision oncology in surgery: patient selection for operable pancreatic cancer. Annals of surgery
7. Shen Y-N, Bai X-L, Jin G et al (2018) A preoperative nomogram predicts prognosis of up front resectable patients with pancreatic cancer head and suspected venous invasion. HPB: the official journal of the International Hepato Pancreato Biliary Association 20:1034–1043
8. Hwang SH, Kim HY, Lee EJ, et al. (2019) Preoperative clinical and computed tomography (CT)-based nomogram to predict oncologic outcomes in patients with pancreatic head cancer resected with curative intent: a retrospective study. Journal of clinical medicine; 8
9. Ferrone CR, Kattan MW, Tomlinson JS, Thayer SP, Brennan MF, Warshaw AL (2005) Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 23:7529–7535
10. de Castro SMM, Biere SSAY, Lagarde SM, Busch ORC, van Gulik TM, Gouma DJ (2009) Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreas. The British journal of surgery 96:417–423
11. Xu D, Zhang K, Li M et al (2020) Prognostic nomogram for resected pancreatic adenocarcinoma: a TRIPOD-compliant retrospective long-term survival analysis. World journal of surgery 44:1260–1269
12. You Y, Han IW, Choi DW et al (2019) Nomogram for predicting postoperative pancreatic fistula. HPB: the official journal of the International Hepato Pancreato Biliary Association 21:1436–1445
13. Guo C-X, Shen Y-N, Zhang Q et al (2020) Prediction of postoperative pancreatic fistula using a nomogram based on the updated definition. Annals of surgical treatment and research 98:72–81
14. Okano K, Hirao T, Unno M et al (2015) Postoperative infectious complications after pancreatic resection. The British journal of surgery 102:1551–1560
15. Are C, Afuh C, Raviglione L, Sasson A, Ullrich F, Smith L (2009) Preoperative nomogram to predict risk of perioperative mortality following pancreatic resections for malignancy. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract 13:2152–2162
16. Hill JS, Zhou Z, Simons JP et al (2010) A simple risk score to predict in-hospital mortality after pancreatic resection for cancer. Annals of surgical oncology 17:1802–1807
17. Mayhew D, Mendonca V, Murthy BVS (2019) A review of ASA physical status - historical perspectives and modern developments. Anaesthesia 74:373–379
18. Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien–Dindo classification of surgical complications: five-year experience. Annals of surgery 250:187–196
19. Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien P-A (2013) The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Annals of surgery 258:1–7
20. Bassi C, Marchegiani G, Dervenis C et al (2017) The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 161:584–591
21. Wente MN, Bassi C, Dervenis C et al (2007) Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 142:761–768
22. Wente MN, Veit JA, Bassi C et al (2007) Postpancreactomy hemorrhage (PPH): An International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 142:20–25
23. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group. Critical care (London, England) 8:R204–R212
24. Martinez-Cambor P, Pardo-Fernández JC (2019) The Youden index in the generalized receiver operating characteristic curve context. The international journal of biostatistics 15
25. Zhou Z-R, Wang W-W, Li Y et al (2019) In-depth mining of clinical data: the construction of clinical prediction model with R. Annals of translational medicine 7:796
26. Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CM (2013) A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. Journal of the American College of Surgeons 216:1–14
27. Buscai E, Cauvin T, Fernandez B et al (2019) Intraductal papillary mucinous neoplasms of the pancreas and European guidelines: importance of the surgery type in the decision-making process. BMC surgery 19:115
28. Casadei R, Ricci C, Taffurelli G et al (2017) Prospective validation of a preoperative risk score model based on pancreatic texture to predict postoperative pancreatic fistula after pancreatoduodenectomy. International journal of surgery (London, England) 48:189–194
29. Ferrich V, Merz MK, Waldmann J et al (2011) Neuroendocrine pancreatic tumors are risk factors for pancreatic fistula after pancreatic surgery. Digestive surgery 28:263–269
30. Howe JR, Merchant NB, Conrad C et al (2020) The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 49:1–33
31. Uzunoglu FG, Reeh M, Vettorazzi E et al (2014) Preoperative pancreatic resection (PREPARE) score: a prospective multicenter-based morbidity risk score. Annals of surgery 260:857–863; discussion 863–4
32. Klompmaker S, Peters NA, van Hilst J et al (2019) Outcomes and risk score for Distal pancreatectomy with celiac axis resection (DP-CAR): an international multicenter analysis. Annals of surgical oncology 26:772–781
33. Ellis RJ, Brock Hewitt D, Liu JB et al (2019) Preoperative risk evaluation for pancreatic fistula after pancreaticoduodenectomy. Journal of surgical oncology 119:1128–1134
34. Chang EH, Sugiyama G, Smith MC et al (2020) Obesity and surgical complications of pancreaticoduodenectomy: an observation study utilizing ACS NSQIP. American journal of surgery 220:135–139
35. Brooks MJ, Sutton R, Sarin S (2005) Comparison of surgical risk score, POSSUM and p-POSSUM in higher-risk surgical patients. The British journal of surgery 92:1288–1292
36. Copeland GP, Jones D, Walters M (1991) POSSUM: a scoring system for surgical audit. The British journal of surgery 78:355–360
37. Parikh P, Shiloach M, Cohen ME et al (2010) Pancrectectomy risk calculator: an ACS-NSQIP resource. HPB : the official journal of the International Hepato Pancreato Biliary Association 12:488–497
38. Pratt W, Joseph S, Callery MP, Vollmer CM (2008) POSSUM accurately predicts morbidity for pancreatic resection. Surgery 143:8–19
39. Lee H, Lee JK, Kang SS et al (2007) Is there any clinical or radiologic feature as a preoperative marker for differentiating mass-forming pancreatitis from early-stage pancreatic adenocarcinoma? Hepato-gastroenterology 54:2134–2140
40. Roch AM, Ceppa EP, Al-Haddad MA et al (2014) The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression. Annals of surgery 260:680–8; discussion 688–90
41. Frebourg T, Bercoff E, Manchon N et al (1988) The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 62:2287–2290
42. Graves AJ, Holmquist DR, Githens S (1986) Effect of duct obstruction on histology and on activities of gamma-glutamyl transferase, adenosine triphosphatase, alkaline phosphatase, and amylase in rat pancreas. Digestive diseases and sciences 31:1254–1264
43. Maggino L, Liu JB, Ecker BL, Pitt HA, Vollmer CM (2018) Impact of operative time on outcomes after pancreatic resection: a risk-adjusted analysis using the American College of Surgeons NSQIP Database. Journal of the American College of Surgeons 226:844–857.e3
44. Halter J, Mahar AL, Tsang ME et al (2015) The impact of perioperative blood transfusions on post-pancreatectomy short-term outcomes: an analysis from the American College of Surgeons National Surgical Quality Improvement Program. HPB : the official journal of the International Hepato Pancreato Biliary Association 17:975–982
45. Zhang L, Liao Q, Zhang T, Dai M, Zhao Y (2016) Blood transfusion is an independent risk factor for postoperative serious infectious complications after pancreaticoduodenectomy. World journal of surgery 40:2507–2512
46. Lammi J-P, Eskelinen M, Tuimala J, Saarnio J, Rantanen T (2019) Blood transfusions in major pancreatic surgery: a 10-year cohort study including 1404 patients undergoing pancreatic resections in Finland. Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society 108:210–215
47. Kühlbrey CM, Samiei N, Sick O, Makowiec F, Hopt UT, Wittel UA (2017) Pancreatitis after pancreatoduodenectomy predicts clinically relevant postoperative pancreatic fistula. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 21:330–338
48. Cloyd JM, Kastenberg ZJ, Visser BC, Poultsides GA, Norton JA (2014) Postoperative serum amylase predicts pancreatic fistula formation following pancreatoduodenectomy. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 18:348–353
49. Sandini M, Maleo G, Gianotti L (2016) Scores for prediction of fistula after pancreatoduodenectomy: a systematic review. Digestive surgery 33:392–400
50. Bertens KA, Crown A, Clanton J et al (2017) What is a better predictor of clinically relevant postoperative pancreatic fistula (CR-POPF) following pancreatoduodenectomy (PD): postoperative day one drain amylase (POD1DA) or the fistula risk score (FRS)? HPB : the official journal of the International Hepato Pancreato Biliary Association 19:75–81
51. Linnemann RJA, Patijn GA, van Rijssen LB, et al (2019) The role of abdominal drainage in pancreatic resection - a multicenter validation study for early drain removal. Pancreatology : official journal of the International Association of Pancreatology (IAP) […] [et al.]; 19: 888–96
52. Sukharamwala P, Prashant S, Thoens J et al (2012) Advanced age is a risk factor for post-operative complications and mortality after a pancreatoduodenectomy: a meta-analysis and systematic review. HPB : the official journal of the International Hepato Pancreateo Biliary Association 14:649–657
53. O’Brien MM, Gonzales R, Shroyer AL et al (2002) Modest serum creatinine elevation affects adverse outcome after general surgery. Kidney international 62:585–592
54. Zarbock A, Koyner JL, Hoste EAJ, Kellum JA (2018) Update on perioperative acute kidney injury. Anesthesia and analgesia 127:1236–1245
55. Frasson M, Flor-Lorente B, Rodríguez JLR et al (2015) Risk factors for anastomotic leak after colon resection for cancer: multivariate analysis and nomogram from a multicentric, prospective, national study With 3193 patients. Annals of surgery 262:321–330
56. Pecorelli N, Capretti G, Sandini M et al (2018) Impact of sarcopenic obesity on failure to rescue from major complications following pancreatoduodenectomy for cancer: results from a multicenter study. Annals of surgical oncology 25:308–317
57. Shimizu Y, Yamaue H, Maguchi H et al (2015) Validation of a nomogram for predicting the probability of carcinoma in patients with intraductal papillary mucinous neoplasm in 180 pancreatic resection patients at 3 high-volume centers. Pancreas 44:459–464
58. Al Efshat MA, Attiyeh MA, Eaton AA et al (2018) Multi-institutional validation study of pancreatic cyst fluid protein analysis for prediction of high-risk intraductal papillary mucinous neoplasms of the pancreas. Annals of surgery 268:340–347

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.